Status:
COMPLETED
Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. T...
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. T...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria
- Disease duration ≤ 24 months
- Disease progression in the past 3 months
- Score ≥ 2 at the item "swallowing" of the ALS Functional Rating Scale Revised
- Score ≥ 2 at the item "walking" of the ALS Functional Rating Scale Revised
- Treatment with steady regimen of riluzole for a minimum of 1 month before study entry, and desiring its continuation
- Able to give informed consent
- Written informed consent
Exclusion
- Motor neuron diseases other than ALS
- Severe head trauma in the past
- History of seizures
- History of ischemic stroke or hemorrhage
- Pacemaker
- Metal implants in the head/neck region
- Severe comorbidity
- Intake of illegal drugs
- Pregnancy
Key Trial Info
Start Date :
October 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03293394
Start Date
October 2 2017
End Date
July 1 2018
Last Update
March 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AO Spedali Civili
Brescia, BS, Italy, 25100